Free Trial
NASDAQ:MDGL

Madrigal Pharmaceuticals Q3 2023 Earnings Report

Madrigal Pharmaceuticals logo
$345.73 +3.44 (+1.00%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$353.35 +7.62 (+2.20%)
As of 08/8/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Madrigal Pharmaceuticals EPS Results

Actual EPS
-$5.34
Consensus EPS
-$4.90
Beat/Miss
Missed by -$0.44
One Year Ago EPS
N/A

Madrigal Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Madrigal Pharmaceuticals Announcement Details

Quarter
Q3 2023
Time
Before Market Opens
Conference Call Date
Monday, November 6, 2023
Conference Call Time
7:00AM ET

Madrigal Pharmaceuticals Earnings Headlines

Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
See More Madrigal Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Madrigal Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Madrigal Pharmaceuticals and other key companies, straight to your email.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals (NASDAQ:MDGL), a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

View Madrigal Pharmaceuticals Profile

More Earnings Resources from MarketBeat